Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. [electronic resource]
Producer: 20130110Description: 1241-8 p. digitalISSN:- 1097-685X
- Administration, Oral
- Adrenergic beta-Antagonists -- administration & dosage
- Aged
- Aged, 80 and over
- Anti-Arrhythmia Agents -- administration & dosage
- Anti-Inflammatory Agents -- administration & dosage
- Antioxidants -- administration & dosage
- Arginine -- analogs & derivatives
- Atrial Fibrillation -- blood
- Biomarkers -- blood
- Bisoprolol -- administration & dosage
- C-Reactive Protein -- metabolism
- Coronary Artery Bypass -- adverse effects
- Creatine Kinase, MB Form -- blood
- Drug Administration Schedule
- Fatty Acid Binding Protein 3
- Fatty Acid-Binding Proteins -- blood
- Female
- Hemodynamics -- drug effects
- Humans
- Infusions, Intravenous
- Japan
- Male
- Middle Aged
- Morpholines -- administration & dosage
- Natriuretic Peptide, Brain -- blood
- Pilot Projects
- Serum Amyloid P-Component -- metabolism
- Single-Blind Method
- Time Factors
- Treatment Outcome
- Troponin I -- blood
- Urea -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.